Peer-Reviewed Publications

      Structural, functional, and molecular impact on the cardiovascular system in ApoE-/- mice exposed to aerosol from candidate modified risk tobacco products, Carbon Heated Tobacco Product 1.2 and Tobacco Heating System 2.2, compared with cigarette smoke

      Szostak, J.; Titz, B.; Schlage, W. K.; Guedj, E.; Sewer, A.; Phillips, B.; Leroy, P.; Buettner, A.; Neau, L.; Trivedi, K.; Martin, F.; Ivanov, N. V.; Vanscheeuwijck, P.; Peitsch, M. C.; Hoeng, J.

      Published
      Nov 6, 2019
      DOI
      10.1016/j.cbi.2019.108887
      PMID
      31705857
      Link to publication
      Topic
      Summary

      Aim: To investigate the molecular, structural, and functional impact of aerosols from candidate modified risk tobacco products (CMRTP), the Carbon Heated Tobacco Product (CHTP) 1.2 and Tobacco Heating System (THS) 2.2, compared with that of mainstream cigarette smoke (CS) on the cardiovascular system of ApoE−/- mice. Methods: Female ApoE−/- mice were exposed to aerosols from THS 2.2 and CHTP 1.2 or to CS from the 3R4F reference cigarette for up to 6 months at matching nicotine concentrations. A Cessation and a Switching group (3 months exposure to 3R4F CS followed by filtered air or CHTP 1.2 for 3 months) were included. Cardiovascular effects were investigated by echocardiographic, histopathological, immunohistochemical, and transcriptomics analyses. Results: Continuous exposure to CMRTP aerosols did not affect atherosclerosis progression, heart function, left ventricular (LV) structure, or the cardiovascular transcriptome. Exposure to 3R4F CS triggered atherosclerosis progression, reduced systolic ejection fraction and fractional shortening, caused heart LV hypertrophy, and initiated significant dysregulation in the transcriptomes of the heart ventricle and thoracic aorta. Importantly, the structural, functional, and molecular changes caused by 3R4F CS were improved in the smoking cessation and switching groups. Conclusion: Exposure to CMRTP aerosols lacked most of the CS exposure-related functional, structural, and molecular effects. Smoking cessation or switching to CHTP 1.2 aerosol caused similar recovery from the 3R4F CS effects in the ApoE−/- model, with no further acceleration of plaque progression beyond the aging-related rate.

      Related Publications

      Sytems toxicological-based assessment of sex-related differences in response to cigarette smoke within an OECD rat inhalation study

      Systems Toxicology Pre-clinical Toxicology

      Physiologically based Pharmacokinetic Modeling of Nicotine from Inhaled Aqueous Aerosol Predicts Marked Gastrointestinal Absorption in Rats

      Systems Toxicology Pre-clinical Toxicology

      Systems toxicology assessment of a representative e-liquid formulation using human primary bronchial epithelial cells

      Systems Toxicology Pre-clinical Toxicology

      In vitro high-content imaging-based phenotypic analysis of bronchial 3D organotypic air–liquid interface cultures

      Systems Toxicology Pre-clinical Toxicology

      Impact of sample preparation upon intracellular metabolite measurements in 3D cell culture systems

      Systems Toxicology Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.